STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2838 by analyst upside · 2026-08-13
JAZZ
Jazz Pharmaceuticals plc
Healthcare · Market Cap $16B · P/E 17.1x
ANALYST PRICE TARGET
+12.9%
implied upside to consensus target
Current Price $248.94
Consensus Target $281.1
Bull Target $315.0
Bear Target $196.0
Analysts Covering 20
ANALYST CONSENSUS - BUY
Strong Buy
7
Buy
11
Hold
1
Sell
1
52-Week Low $112.49
52-Week High $265.05
YTD Return +43.8%
FUNDAMENTALS
Market Cap $16B
P/E Ratio (TTM) 17.1x
Forward P/E 9.7x
EPS (TTM) $14.60
PEG Ratio 0.96
Dividend Yield N/A
Revenue (TTM) $4.6B
Profit Margin 20.4%
52-WEEK RANGE
52-Week Low $112.49
52-Week High $265.05
Current Price $248.94
Bear Target $196.0
Bull Target $315.0
● Now $248.94 ● Target $281.1
TRADING DATA
Avg Volume 872K
YTD Return +43.8%
Analyst Count 20
Consensus Buy
Upside to Target +12.9%
Last Updated 2026-08-13

ANALYST SUMMARY

Jazz Pharmaceuticals plc (JAZZ) is currently trading at $248.94 with a Wall Street consensus price target of $281.1, implying potential upside of 12.9% over the next 12 months. 20 analysts currently cover JAZZ, with a consensus rating of Buy - 90% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $315.0, while the most cautious has a target of $196.0.

JAZZ operates in the Healthcare sector with a market capitalisation of $16B. The stock is up 43.8% year-to-date and is currently trading near the upper end of its 52-week range of $112.49 – $265.05.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for JAZZ, with each firm's 90-day track record across all stocks we track. See full firm rankings →

B of A Securities - Reiterated
Buy → Buy 2026-06-10 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-05-27 Building track record
Bernstein ● Initiated
Market Perform 2026-05-22 Building track record
Piper Sandler - Reiterated
Overweight → Overweight 2026-05-22 14% win rate (7 calls)
UBS ↑ Upgrade
Neutral → Buy 2026-05-19 33% win rate (6 calls)
TD Cowen - Reiterated
Buy → Buy 2026-05-06 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-05-06 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-05-06 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
65
out of 100
Coverage depth
23/30
Consensus clarity
20/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →